Kardigan Targets Heart Disease on Multiple Fronts at ACC.26

SOUTH SAN FRANCISCO, Calif. – March 17, 2026 – The landscape of cardiovascular medicine may be on the cusp of significant developments as heart health company Kardigan prepares to unveil a sweeping portfolio of data at the American College of Cardiology’s Annual Scientific Session (ACC.26) in New Orleans later this month. The company is set to present findings from all three of its late-stage clinical programs, headlined by a highly anticipated late-breaking presentation on its novel therapy for uncontrolled hypertension.

The series of presentations underscores a deliberate strategy to tackle heart disease from multiple angles, combining targeted pharmaceuticals with advanced clinical intelligence. For a company dedicated to “modernizing cardiovascular drug development,” the upcoming conference represents a pivotal moment to demonstrate the viability of its ambitious, multi-front approach to treating some of the world's most prevalent and challenging health conditions.

A New Offensive Against Uncontrolled Hypertension

The centerpiece of Kardigan’s showcase is the late-breaking Phase 2 data for tonlamarsen. The presentation, part of a joint session with the Journal of the American Medical Association, will reveal results from the KARDINAL study, which evaluates the drug in patients with uncontrolled hypertension—a condition where blood pressure remains dangerously high despite treatment with multiple existing medications.

Tonlamarsen represents a novel approach to a decades-old problem. Unlike traditional drugs that target downstream components, it is an antisense oligonucleotide designed to reduce the liver's production of angiotensinogen, the primary precursor protein in the body's main blood pressure regulation system. By intervening at the very top of the cascade, the therapy has the potential to offer a more profound and sustained blood pressure reduction.

For the millions of patients who struggle with treatment-resistant hypertension, the need for new options is critical. This patient group faces a significantly elevated risk of stroke, heart attack, and kidney failure. If the KARDINAL data demonstrates a strong efficacy and safety profile, tonlamarsen could emerge as a game-changing option, potentially shifting the treatment paradigm from daily multi-pill regimens to a less frequent, targeted subcutaneous therapy.

Tackling the Untreatable in Structural Heart Disease

Beyond hypertension, Kardigan will present data highlighting its efforts to address critical unmet needs in structural heart disease, where treatment options are often limited to surgical intervention.

One key presentation will feature preclinical data on ataciguat, a potential first-in-disease treatment for moderate calcific aortic valve stenosis (CAVS). Currently, there are no approved medications to slow the progression of this condition, which involves the stiffening and narrowing of the heart's aortic valve. Patients are typically monitored in a “watch and wait” approach until their disease becomes severe enough to require invasive valve replacement surgery. Ataciguat, an oral soluble guanylate cyclase activator, is being developed to potentially halt or reverse the underlying calcification process, offering the first-ever pharmacological alternative to this inevitable progression.

Further broadening its pipeline, Kardigan will also share Phase 2 open-label extension data for danicamtiv, a cardiac myosin activator aimed at patients with genetic dilated cardiomyopathy (DCM). This serious condition weakens and enlarges the heart muscle, impairing its ability to pump blood. Danicamtiv is designed to directly target the heart's contractile machinery, restoring cardiac function in patients with specific genetic variants. This highly targeted approach epitomizes the move toward precision medicine in cardiology, treating the underlying genetic driver of the disease rather than just its symptoms.

Beyond the Pill: Integrating AI and Digital Monitoring

Kardigan’s strategy extends beyond novel pharmaceuticals. Prolaio, its clinical intelligence subsidiary, will present findings from its LINK-HF2 trial, demonstrating how continuous monitoring and artificial intelligence can transform heart failure management. The trial explores the use of wearable sensors to capture ECG and activity data, which is then analyzed by proprietary AI algorithms to predict changes in heart failure risk.

This synergy between targeted drugs and smart diagnostics is central to Kardigan's vision. By identifying high-risk patients earlier and monitoring their real-world response to therapy, Prolaio’s platform has the potential to optimize treatment, reduce hospitalizations, and accelerate future clinical trials. This integration represents a significant step toward a more proactive and data-driven ecosystem of care, where digital insights guide the application of powerful new medicines.

A Modern Blueprint for Drug Development

The breadth of Kardigan's pipeline is a direct result of its strategic business model, which relies on in-licensing promising assets from larger pharmaceutical firms—tonlamarsen from Ionis, danicamtiv from Bristol Myers Squibb (via MyoKardia), and ataciguat from Sanofi and Mayo Clinic. This approach allows the company to focus its expertise on late-stage clinical development and patient-centric strategies, bypassing the enormous risks and costs of early-stage discovery to rapidly build a formidable portfolio.

“ACC 2026 is an important meeting for Kardigan as we share data across all three of our late-stage clinical programs, alongside new cardiovascular insights from Prolaio,” said Tassos Gianakakos, CEO of Kardigan, in a statement. “Together, these presentations underscore the depth of our pipeline and our commitment to generating high-quality important evidence... that can meaningfully advance cardiovascular care for patients.”

This commitment is anchored in the pursuit of “functional cures”—a bold ambition to develop medicines that modify the underlying disease pathophysiology so profoundly that patients can move beyond mere symptom management. As the data is unveiled in New Orleans, the medical community will be watching closely to see if Kardigan’s multi-front war on heart disease can deliver on its promise to usher in a new era of personalized cardiovascular care.